Trial Profile
A phase II trial of cisplatin, pemetrexed and bevacizumab in untreated malignant mesothelioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 16 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2006 New trial record.